Zymeworks (ZYME)
(Delayed Data from NSDQ)
$10.40 USD
+0.02 (0.19%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $10.40 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
ZYME 10.40 +0.02(0.19%)
Will ZYME be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ZYME based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ZYME
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
3 Top Stocks to Invest in for Amazing Earnings Acceleration
ZYME: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zymeworks (ZYME) Loses -13.41% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zymeworks (ZYME) Upgraded to Buy: What Does It Mean for the Stock?
Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates
Other News for ZYME
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
Zymeworks’ New Cancer Drug ZW191 Clears FDA Hurdle
Zymeworks says FDA clears IND application for ZW191
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues